表紙
市場調査レポート

医薬品リーダーシリーズ:眼科用薬剤メーカー上位25社の分析 (2016〜2026年)

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026

発行 Visiongain Ltd 商品コード 294342
出版日 ページ情報 英文 220 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=135.00円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品リーダーシリーズ:眼科用薬剤メーカー上位25社の分析 (2016〜2026年) Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026
出版日: 2016年05月31日 ページ情報: 英文 220 Pages
概要

当レポートでは、世界の眼科用薬剤市場について分析し、市場の全体的な構造や動向、市場収益額・成長率の予測値 (今後10年間分)、製品種類別・疾患別・地域別の詳細動向、世界各地の主要メーカー (全25社) および新興企業のプロファイル (収益額予測、治験の進行状況)、今後の市場動向の見通しなどをまとめてお届けします。

第1章 レポート概要

第2章 眼科用薬剤市場のイントロダクション

  • 製薬業界の概要
  • 世界の眼疾患の負担額
  • 眼科用薬剤:市場の内訳
  • 緑内障
  • 加齢性黄斑変性症 (AMD)
  • 糖尿病性網膜症 (DR)
  • 眼アレルギーおよびアレルギー性結膜炎
  • 眼炎症性疾患
  • 眼の感染症
  • ドライアイ症候群
  • 治験のフェーズ (相)
  • 当分析の為替レート

第3章 世界の眼科用薬剤市場

  • 世界の眼科用薬剤市場の最新動向
  • 売上高の予測 (今後11年間分)
  • 代表的な眼科用薬剤
  • 眼科用薬剤市場の代表的企業 (全25社)
  • 分野別の売上高の予測 (今後11年間分)
    • 網膜障害向け薬剤
    • 眼アレルギー・眼炎症性疾患・感染症向け薬剤
    • 緑内障向け薬剤
    • ドライアイ向け薬剤
    • その他の眼科用薬剤
  • 市場シェアの変化の見通し
  • 世界の眼科用薬剤市場の促進・抑制要因
    • 市場促進要因
    • 市場抑制要因

第4章 米国の代表的な眼科用薬剤メーカー

  • Allergan
    • 製品ポートフォリオ
    • 治験の最終段階にあるパイプライン製品
    • 市場収益額の予測 (今後11年間分)
      • 市場シェアの予測 (今後11年間分)
    • SWOT分析
  • Pfizer
  • Regeneron
  • Akorn

第5章 欧州の代表的な眼科用薬剤メーカー

  • Bayer
  • Novartis (Alconを含む)
  • Roche

第6章 アジア太平洋地域の代表的な眼科用薬剤メーカー

  • 参天製薬
  • 千寿製薬
  • Valeant

第7章 新興眼科用薬剤メーカー

  • 小規模な製品ポートフォリオと有望なパイプライン候補薬を有する企業
  • Acucela
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics (AKB 9778)
  • Alimera Sciences (Iluvien、NADPH Oxidase阻害薬)
  • Amakem
  • Ampio Pharmaceuticals
  • Chengdu Kanghong Pharmaceutical
  • Eleven Biotherapeutics
  • EyeGate Pharmaceuticals
  • Gene Signal (Aganirsen)
  • Icon Bioscience
  • MacuCLEAR (MC 1101)
  • Neurotech
  • Omeros
  • OphthaliX (Can-Fite BioPharma)
  • Ophthotech (Fovista, Zimura)
  • 大塚製薬
  • pSivida Corp.
  • RXi Pharmaceuticals
  • Shire (Lifitegrast (SHP606), Premiplex (SHP607))
  • ThromboGenics (Jetrea, ThromboGgenics)

第8章 眼科用薬剤市場の定性的分析

  • ポーターのファイブフォース分析:眼科用薬剤市場の場合
    • 同一他社との競合:中
    • 新規参入企業の脅威:低
    • サプライヤーの交渉力:低
    • バイヤーの購買力:中
    • 代替製品の脅威:中

第9章 結論

  • 眼科用薬剤:成長中のニッチ市場
  • 世界の眼科用薬剤市場
  • 眼科用薬剤市場の将来予測 (今後11年間分)
  • 眼科用薬剤市場の将来像
    • 専門企業への市場収益額の集中
    • ジェネリック医薬品の普及
    • 小企業が大きな影響を与える可能性
    • 眼科用薬剤市場で勝ち抜く企業

第10章 用語一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0120

What can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market.

Our 220-page report provides 160 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

In the report also you will find revenue forecasts to 2026 for the following submarkets in the ophthalmic drugs market:

  • Retinal Disorder Drugs
  • Allergic, Inflammatory & Infective Drugs
  • Glaucoma Drugs
  • Dry Eye Drugs
  • Other Ophthalmic Drugs

image1

The report provides detailed profiles and revenue forecasts to 2026 for the following key companies operating within the ophthalmic drugs market:

  • Novartis
  • Regeneron
  • Allergan
  • Roche
  • Valeant
  • Santen
  • Bayer
  • Pfizer
  • Senju
  • Akorn

The report also includes revenue forecasts to 2026 for the following ophthalmic drugs:

  • Eylea
  • Lucentis
  • Restasis
  • Lumigan and Ganfort
  • Travatan/Travatan Z and DuoTrav
  • Alphagan/Alphagan P and Combigan
  • Vigamox
  • Xalatan/Xalacom
  • Azopt
  • Jetrea
  • Hyalein
  • Cosopt
  • Tapros/Taflotan
  • Diquas
  • Cravit
  • Alesion
  • Lotemax

Leading companies and potential for market growth

Novartis (including subsidiary Alcon) will remain the leading ophthalmic company to 2026, our work forecasts. We predict strong revenue growth across the ophthalmic drugs market through to 2026. Advances in ocular drug delivery, treatments which address areas of unmet clinical need and the launch of several new therapies across all submarkets will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of over 25 leading companies, including these:

  • Novartis
  • Regeneron
  • Allergan
  • Roche
  • Valeant
  • Santen
  • Bayer
  • Pfizer
  • Senju
  • Akorn

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Revenue forecasts to 2016 for ophthalmic drugs marketed by the company
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the ophthalmic drugs industry?

Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of key therapeutic indications
  • Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026 report helps you

In summary, our 220-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the 10 leading companies in the market - discover the industry's prospects for companies including: Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju and Akorn
  • Revenue forecasts to 2026 for each major submarket - discover prospects for leading ophthalmic drugs in the following areas: retinal disorder drugs, allergic, inflammatory & infective drugs, glaucoma drugs and dry eye drugs.
  • Revenue forecasts to 2026 for 17 leading drugs - discover prospects for leading ophthalmic drugs including: Eylea, Lucentis, Restasis, Lumigan and Ganfort, Travatan/Travatan Z and DuoTrav, Alphagan/Alphagan P and Combigan, Vigamox, Xalatan/Xalacom, Azopt, Jetrea, Hyalein, Cosopt, Tapros/Taflotan, Diquas, Cravit, Alesion and Lotemax.
  • Assessment of 21 emerging ophthalmic companies - analysis of products, revenue, mergers & acquisitions and leading pipeline drug candidates
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

Table of Contents

1. Report Overview

  • 1.1 Global Ophthalmic Drugs Market Overview
  • 1.2 Global Ophthalmic Drugs Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Introduction to Ophthalmic Drugs

  • 2.1 The Pharmaceutical Industry: a Very Brief Overview
  • 2.2 The Global Burden of Eye Disease
  • 2.3 Ophthalmic Drugs: Market Segmentation
  • 2.4 Glaucoma: the 'Silent Thief of Sight'
    • 2.4.1 A Classification of Glaucoma
      • 2.4.1.1 Primary Open-Angle Glaucoma
      • 2.4.1.2 Acute Angle-Closure Glaucoma
      • 2.4.1.3 Congenital Glaucoma
      • 2.4.1.4 Secondary Glaucoma
      • 2.4.1.5 Normal-Tension Glaucoma
      • 2.4.1.6 Ocular Hypertension
    • 2.4.2 Risk Factors for Glaucoma
    • 2.4.3 Diagnosis of Glaucoma
    • 2.4.4 Drug Treatment of Glaucoma
    • 2.4.5 Laser Treatment and Surgery for Glaucoma
  • 2.5 Age-Related Macular Degeneration (AMD)
    • 2.5.1 Dry (non-exudative) AMD
    • 2.5.2 Wet (exudative) AMD
    • 2.5.3 Risk Factors for AMD
    • 2.5.4 Diagnosis of AMD
    • 2.5.5 Treatment of AMD
  • 2.6 Diabetic Retinopathy (DR)
    • 2.6.1 Diagnosis of Diabetic Retinopathy
    • 2.6.2 Treatment of Diabetic Retinopathy
  • 2.7 Ocular Allergy and Allergic Conjunctivitis
    • 2.7.1 Diagnosis of Ocular Allergy
    • 2.7.2 Treatment of Ocular Allergy
  • 2.8 Ocular Inflammatory Disease
    • 2.8.1 Treatment of Ocular Inflammatory Disease
  • 2.9 Eye Infections
    • 2.9.1 Treatment of Eye Infections
  • 2.10 Dry Eye Syndrome
    • 2.10.1 Treatment of Dry Eye Syndrome
  • 2.11 Phases of Clinical Trials
  • 2.12 Currency Exchange Rates in This Report

3. Ophthalmic Drugs: World Market 2016-2026

  • 3.1 The World Ophthalmic Drugs Market in 2015
  • 3.2 World Ophthalmic Drugs Market: Sales Forecast 2016-2026
  • 3.3 Leading Ophthalmic Drugs
  • 3.4 Leading Companies in the Ophthalmic Drugs Market
    • 3.4.1 Top 25 Ophthalmic Drug Manufacturers
  • 3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2016-2026
    • 3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2016-2026
    • 3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2016-2026
    • 3.5.3 Glaucoma Drugs Market: Sales Forecast 2016-2026
    • 3.5.4 Dry Eye Drugs Market: Sales Forecast 2016-2026
    • 3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2016-2026
  • 3.6 How Will Market Shares Change to 2026?
  • 3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2016-2026
    • 3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers
    • 3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints

4. Leading US Ophthalmic Drug Manufacturers 2016-2026

  • 4.1 Allergan Overview
    • 4.1.1 Allergan: Ophthalmic Product Portfolio
      • 4.1.1.1 Restasis: Generic Launch in 2016?
      • 4.1.1.2 Restasis: Sales Forecast 2016-2026
      • 4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
      • 4.1.1.4 Lumigan and Ganfort: Sales Forecast 2016-2026
      • 4.1.1.5 Refresh Brand Products: the Range
      • 4.1.1.6 Alphagan/Alphagan P and Combigan: Extended Lifecycle
      • 4.1.1.7 Alphagan/Alphagan P and Combigan: Sales Forecast 2016-2026
      • 4.1.1.8 Acular: New Forms Receiving FDA Approvals
      • 4.1.1.9 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Edema
    • 4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline
    • 4.1.3 Allergan: Ophthalmic Revenue Forecast 2016-2026
      • 4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2016-2026
    • 4.1.4 Allergan: SWOT Analysis
  • 4.2 Pfizer Overview
    • 4.2.1 Pfizer: Ophthalmic Product Portfolio
      • 4.2.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
      • 4.2.1.2 Xalatan/Xalacom: Sales Forecast 2016-2026
    • 4.2.2 Pfizer: Ophthalmic Product Pipeline
    • 4.2.3 Pfizer: Revenue Forecast 2016-2026
      • 4.2.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2016-2026
    • 4.2.4 Pfizer: SWOT Analysis
  • 4.3 Regeneron Overview
    • 4.3.1 Regeneron: Ophthalmic Product Portfolio
      • 4.3.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
      • 4.3.1.2 Eylea: US Sales Forecast 2016-2026
    • 4.3.2 Regeneron: Ophthalmic Product Pipeline
    • 4.3.3 Regeneron: Revenue Forecast 2016-2026
      • 4.3.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2016-2026
    • 4.3.4 FDA Approves Zaltrap (aflibercept)
    • 4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
    • 4.3.6 Regeneron: SWOT Analysis
  • 4.4 Akorn Overview
    • 4.4.1 Akorn: Ophthalmic Product Portfolio
      • 4.4.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
      • 4.4.1.2 Cosopt/Cosopt PF: Acquired from Merck
    • 4.4.2 Akorn: Revenue Forecast 2016-2026
      • 4.4.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2016-2026
    • 4.4.3 Akorn: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers 2016-2026

  • 5.1 Bayer Overview
    • 5.1.1 Bayer: Ophthalmic Product Pipeline
    • 5.1.2 Eylea: non-US Sales Forecast 2016-2026
    • 5.1.3 Bayer: Revenue Forecast 2016-2026
      • 5.1.3.1 Bayer: Ophthalmic Drugs Market Share Forecast 2016-2026
  • 5.2 Novartis (including Alcon) Overview
    • 5.2.1 Novartis: Ophthalmic Product Portfolio
      • 5.2.1.1 Lucentis: Still a Leading Drug in AMD
      • 5.2.1.2 Lucentis: Non-US Sales Forecast 2016-2026
      • 5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
      • 5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2016-2026
      • 5.2.1.5 Vigamox: Competes with Alcon's Moxeza
      • 5.2.1.6 Vigamox: Sales Forecast 2016-2026
      • 5.2.1.7 Azopt: Marketed in Major Markets
      • 5.2.1.8 Azopt: Sales Forecast 2016-2026
      • 5.2.1.9 Jetrea: Sales Revenues Fall Short
      • 5.2.1.10 Jetrea: Non-US Sales Forecast 2016-2026
    • 5.2.2 Novartis: Ophthalmic Product Pipeline
      • 5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
      • 5.2.2.2 AKB 9778 (Aerpio Therapeutics)
    • 5.2.3 Novartis: Revenue Forecast 2016-2026
      • 5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2016-2026
    • 5.2.4 Novartis: SWOT Analysis
  • 5.3 Roche Overview
    • 5.3.1 Roche: Ophthalmic Product Portfolio
      • 5.3.1.1 Lucentis: US Sales Forecast 2016-2026
      • 5.3.1.2 Avastin: Off-Label Use for Wet AMD Cannibalising Lucentis Sales
      • 5.3.1.3 Avastin: Sales Forecast 2016-2026
    • 5.3.2 Roche: Ophthalmic Product Pipeline
      • 5.3.2.1 Lampalizumab (RG7417)
    • 5.3.3 Roche: Revenue Forecast 2016-2026
      • 5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2016-2026
    • 5.3.4 Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2016-2026

  • 6.1 Santen Overview
    • 6.1.1 Santen: Ophthalmic Product Portfolio
      • 6.1.1.1 Eylea: Japan Sales Forecast 2016-2026
      • 6.1.1.2 Hyalein
      • 6.1.1.3 Hyalein: Sales Forecast 2016-2026
      • 6.1.1.4 Cosopt: Non-US Sales Forecast 2016-2026
      • 6.1.1.5 Tapros/Taflotan: Sales Forecast 2016-2026
      • 6.1.1.6 Diquas: Sales Forecast 2016-2026
      • 6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
      • 6.1.1.8 Cravit: Sales Forecast 2016-2026
      • 6.1.1.9 Alesion: Sales Forecast 2016-2026
    • 6.1.2 Santen: Ophthalmic Product Pipeline
    • 6.1.3 Santen: Revenue Forecast 2016-2026
      • 6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2016-2026
    • 6.1.4 Santen: SWOT Analysis
  • 6.2 Senju Overview
    • 6.2.1 Senju: Ophthalmic Product Portfolio
    • 6.2.2 Senju: Ophthalmic Product Pipeline
      • 6.2.2.1 Y 39983 (SNJ 1656)
      • 6.2.2.2 Difluprednate (SJE-2079)
    • 6.2.3 Senju: Revenue Forecast 2016-2026
      • 6.2.3.1 Senju: Ophthalmic Drugs Market Share Forecast 2016-2026
    • 6.2.4 Senju: SWOT Analysis
  • 6.3 Valeant Overview
    • 6.3.1 Valeant: Ophthalmic Product Portfolio
      • 6.3.1.1 Lotemax: New Formulation Launch Expected in 2016
      • 6.3.1.2 Lotemax: Sales Forecast 2016-2026
    • 6.3.2 Valeant: Ophthalmic Product Pipeline
      • 6.3.2.1 Vesneo (Latanoprostene Bunod)
      • 6.3.2.2 Brimonidine tartarate 0.0025% for Eye Whitening (Valeant)
    • 6.3.3 Valeant: Revenue Forecast 2016-2026
      • 6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2016-2026
    • 6.3.4 Valeant: SWOT Analysis
      • 6.3.4.1 Valeant's Acquisition of Bausch and Lomb: Aggressive Expansion?
      • 6.3.4.2 Valeant: Difficult End to 2015 Puts Company Future in Doubt

7. Emerging Ophthalmic Drug Manufacturers in 2016

  • 7.1 Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2016
  • 7.2 Acucela
  • 7.3 Aerie Pharmaceuticals
  • 7.4 Aerpio Therapeutics: Developing AKB 9778
  • 7.5 Alimera Sciences
    • 7.5.1 Iluvien: Increasing Geographical Reach and Increasing Sales
    • 7.5.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
  • 7.6 Amakem
  • 7.7 Ampio Pharmaceuticals
  • 7.8 Chengdu Kanghong Pharmaceutical
  • 7.9 Eleven Biotherapeutics
  • 7.10 EyeGate Pharmaceuticals
  • 7.11 Gene Signal
    • 7.11.1 Aganirsen: Preventing Corneal Graft Rejection
  • 7.12 Icon Bioscience
  • 7.13 MacuCLEAR
    • 7.13.1 MC 1101: a Potential Therapy for Dry AMD
  • 7.14 Neurotech
  • 7.15 Omeros
  • 7.16 OphthaliX (Can-Fite BioPharma)
  • 7.17 Ophthotech
    • 7.17.1 Fovista: Potential Game-Changer in AMD
    • 7.17.2 Fovista: Significant Improvement on Lucentis in Phase II Trials
    • 7.17.3 Zimura: Complement C5 Inhibitor
  • 7.18 Otsuka Pharmaceutical
  • 7.19 pSivida Corp.
  • 7.20 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
  • 7.21 Shire
    • 7.21.1 Lifitegrast (SHP606) for Dry Eye
    • 7.21.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
  • 7.22 ThromboGenics
    • 7.22.1 Jetrea (ocriplasmin)
    • 7.22.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline

8. Qualitative Analysis of the Ophthalmic Drugs Market 2016-2026

  • 8.1 Porter's Five Forces Analysis of the Ophthalmic Drugs Market
    • 8.1.1 Rivalry Among Competitors [Medium]
    • 8.1.2 Threat of New Entrants [Low]
    • 8.1.3 Power of Suppliers [Low]
    • 8.1.4 Power of Buyers [Medium]
    • 8.1.5 Threat of Substitutes [Medium]

9. Conclusions

  • 9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
  • 9.2 The World Ophthalmic Drugs Market in 2015
    • 9.2.1 Leading Ophthalmic Drugs Market Segments
    • 9.2.2 Leading Ophthalmic Drugs
    • 9.2.3 Leading Ophthalmic Drugs Companies
  • 9.3 World Ophthalmic Drugs Market Forecast 2016-2026
  • 9.4 The Future of the Ophthalmic Drugs Market?
    • 9.4.1 Increasing Revenue Concentration among Specialist Companies
    • 9.4.2 The Rise of Generics
    • 9.4.3 Small Companies Can Have a Big Impact
    • 9.4.4 What Will Succeed in the Ophthalmic Drugs Market?

10. Glossary

Appendix

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 2.1 ICD-10 Classification of Visual Impairment, 2010
  • Table 2.2 Drug Treatments for Glaucoma, 2016
  • Table 2.3 Drug Treatments for AMD, 2016
  • Table 2.4 Drug Treatments for Ocular Allergy, 2016
  • Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2016
  • Table 2.6 Selected Drug Treatments for Eye Infections, 2016
  • Table 2.7 Clinical Trial Phases
  • Table 2.8 Currency Exchange Rates, 2015
  • Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2015
  • Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2015
  • Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2015
  • Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2015
  • Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2015-2026
  • Table 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2026
  • Table 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2026
  • Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2015, 2020 and 2026
  • Table 4.1 Allergan: Overview, 2016
  • Table 4.2 Allergan: Ophthalmic Drug Products, Revenue ($m), Growth Rate (%), 2014 and 2015
  • Table 4.3 Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 4.5 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 4.6 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 4.7 Allergan: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 4.8 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
  • Table 4.9 Pfizer: Overview, 2016
  • Table 4.10 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 4.11 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 4.12 Pfizer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 4.13 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
  • Table 4.14 Regeneron: Overview, 2016
  • Table 4.15 Regeneron: Eylea Revenue ($m), AGR (%) and CAGR(%) 2015-2026
  • Table 4.16 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 4.17 Regeneron: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 4.18 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
  • Table 4.19 Akorn: Overview, 2016
  • Table 4.20 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 4.21 Akorn: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 4.22 Akorn: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
  • Table 5.1 Bayer: Overview, 2016
  • Table 5.2 Bayer: Eylea Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.3 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.4 Bayer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 5.5 Novartis: Overview, 2016
  • Table 5.6 Novartis: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.7 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.8 Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.9 Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.10 Novartis: Jetrea Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.11 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.12 Novartis: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 5.13 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
  • Table 5.14 Roche: Overview, 2016
  • Table 5.15 Roche: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.16 Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.17 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 5.18 Roche: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 5.19 Roche: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
  • Table 6.1 Santen: Overview, 2016
  • Table 6.2 Santen: Revenue ($m) and Revenue Share (%) by Segment, FY 2015
  • Table 6.3 Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2016
  • Table 6.4 Santen: Major Prescription Ophthalmic Drugs, Revenue ($m), Revenue Share (%), FY 2015
  • Table 6.5 Santen: Eylea Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.6 Santen: Hyalein Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.7 Santen: Cosopt Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.8 Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.9 Santen: Diquas Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.10 Santen: Cravit Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.11 Santen: Alesion Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.12 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.13 Santen: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 6.14 Santen: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
  • Table 6.15 Senju: Overview, 2016
  • Table 6.16 Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2015
  • Table 6.17 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.18 Senju: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 6.19 Senju: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
  • Table 6.20 Valeant: Overview, 2016
  • Table 6.21 Valeant: Lotemax Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.22 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
  • Table 6.23 Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
  • Table 6.24 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
  • Table 7.1 Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country, 2015
  • Table 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), 2015, 2020 and 2026

List of Figures

  • Figure 1.1 Global Causes of Visual Impairment (% of cases), 2012
  • Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015-2026
  • Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2016
  • Figure 2.1 Estimated Global Prevalence of Visual Impairment (millions of people), 2010
  • Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2013
  • Figure 2.3 Global Causes of Visual Impairment (% of cases), 2013
  • Figure 2.4 Classification of Glaucoma, 2016
  • Figure 2.5 Global Causes of Blindness (% of cases), 2013
  • Figure 3.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2015
  • Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2015
  • Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m) and AGR(%), 2015-2026
  • Figure 3.4 Top 10 Ophthalmic Drugs: Market Share (%), 2015
  • Figure 3.5 Top 10 Ophthalmic Drugs: Revenues ($m), 2015
  • Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenues ($m), 2015
  • Figure 3.7 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2015
  • Figure 3.8 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 3.9 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2015-2026
  • Figure 3.10 Glaucoma Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 3.12 Other Ophthalmic Drugs Market Forecast: Revenues ($m), 2015-2026
  • Figure 3.13 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2015
  • Figure 3.14 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2020
  • Figure 3.15 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2026
  • Figure 3.16 World Ophthalmic Drugs Market: Drivers and Restraints, 2016-2026
  • Figure 4.1 Allergan: Restasis Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.3 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.4 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.5 Allergan: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
  • Figure 4.6 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2015-2026
  • Figure 4.7 Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.8 Pfizer: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
  • Figure 4.9 Regeneron: Eylea Revenue ($m) and AGR(%), 2015-2026
  • Figure 4.10 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
  • Figure 4.11 Regeneron: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
  • Figure 4.12 Akorn: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
  • Figure 4.13 Akorn: Ophthalmic Drugs Market Share (%), 2015-2026
  • Figure 5.1 Bayer: Eylea Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.3 Bayer: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
  • Figure 5.4 Novartis: Lucentis Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.6 Novartis: Vigamox Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.7 Novartis: Azopt Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.8 Novartis: Jetrea Revenue ($m) and AGR(%), 2014-2025
  • Figure 5.9 Novartis: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.10 Novartis: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
  • Figure 5.11 Roche: Lucentis Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.12 Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.13 Roche: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
  • Figure 5.14 Roche: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
  • Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2015
  • Figure 6.2 Santen: Major Prescription Ophthalmic Drugs, Revenue Share (%), FY 2015
  • Figure 6.3 Santen: Eylea Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.4 Santen: Hyalein Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.5 Santen: Cosopt Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.6 Santen: Tapros/Taflotan Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.7 Santen: Diquas Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.8 Santen: Cravit Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.9 Santen: Alesion Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.11 Santen: Ophthalmic Drugs Market Share (%), 2015-2026
  • Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.13 Senju: Ophthalmic Drugs Market Share (%), 2015-2026
  • Figure 6.14 Valeant: Lotemax Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.15 Valeant: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
  • Figure 6.16 Valeant: Ophthalmic Drugs Market Share (%), 2015-2026
  • Figure 7.1 Gene Signal: Ophthalmic Drug Pipeline Progress, 2016
  • Figure 7.2 Ophthotech: Ophthalmic Drug Pipeline Progress, 2015
  • Figure 7.3 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress, 2016
  • Figure 7.4 Shire: Ophthalmic Drug Pipeline Progress, 2016
  • Figure 8.1 Porter's Five Forces Analysis of the Ophthalmic Drugs Market, 2016-2026
  • Figure 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), 2015, 2020 and 2026

Companies Listed

  • Actavis
  • Acucela
  • Advanced Vision Research
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics, Inc
  • Alcon
  • Akorn
  • Algeta
  • Alimera Sciences
  • Allergan
  • Allegro Ophthalmics
  • Amakem
  • Ampio Pharmaceuticals
  • Asahi Glass
  • Aton Pharma, Inc.
  • Aventis
  • AYUMI Pharmaceutical Corporation
  • Banyu Pharmaceutical
  • Barr Laboratories
  • Bausch & Lomb
  • Bayer AG
  • Bayer HealthCare
  • Bayer Yakuhin
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Chiron Corporation
  • Chugai Pharmaceutical
  • Ciba-Geigy
  • Ciba Vision
  • Chengdu Kanghong Pharmaceutical
  • Eleven Biotherapeutics
  • Eli Lilly
  • EyeGate Pharmaceuticals
  • Eyetech Inc.
  • Fougera Pharmaceuticals
  • Genentech
  • Gene Signal
  • GSK
  • Hi-Tech
  • Hospira Inc
  • ICN Pharmaceuticals
  • Icon Bioscience
  • Inception Sciences, Inc.
  • InSite Vision
  • Inspire Pharmaceuticals
  • ISTA Pharmaceuticals
  • Jenapharm
  • Kestrel Ophthalmics
  • King Pharmaceuticals
  • Kyorin Pharmaceutical
  • Kyowa Hakko Kirin
  • LEO Pharma
  • MacuCLEAR
  • MacuSight, Inc.
  • MAP Pharmaceuticals
  • MEAgate International FZLLC
  • Meda
  • Medicis Corporation
  • Merck & Co.
  • MerLion
  • MSD K.K.
  • Mystic Pharmaceuticals
  • Nestlé
  • Neurotech
  • Nippon Boehringer Ingelheim Co.,Ltd.
  • NovaBay Pharmaceuticals
  • Novagali Pharma
  • Novartis International AG
  • Novartis Institutes for BioMedical Research
  • Novartis Venture Funds
  • OcuSciences
  • Omeros
  • OphthtaliX
  • Ophthotech
  • Ora, Inc.
  • Otsuka Pharmaceutical
  • Parke-Davis
  • Par Pharmaceutical
  • Pfizer Inc.
  • Pharmacia
  • Philidor
  • PreCision Dermatology
  • Premacure
  • Procter & Gamble
  • pSivida Corp.
  • Quark Pharmaceuticals
  • Regeneron
  • Rekitt Benckiser
  • Roche Consumer Health
  • RXi Pharmaceuticals
  • Salix
  • Sandoz
  • Sanofi
  • Sanofi-Aventis
  • Santaris Pharma
  • Santen Pharmaceutical Co.
  • Santen S.A.S.
  • SARcode Bioscience
  • Schering AG
  • Senju Pharmaceutical Company Ltd.
  • Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd.
  • Senju USA Inc.
  • Shire
  • SkinMedica
  • Spark Therapeutics
  • Steigerwald
  • ThromboGenics
  • Upjohn
  • Valeant Pharmaceuticals International Ventana Medical Systems
  • Versant Ventures
  • VersaPharm
  • Warburg Pincus LLC
  • Warner-Lambert
  • Wyeth Pharmaceuticals
  • Zoetis
  • Organisations Mentioned in the Report
  • A*STAR Institute for Infocomm Research (Singapore)
  • American Academy of Ophthalmology (AAO)
  • American Diabetes Association
  • American Society of Retina Specialists (ASRS)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • Emory University
  • European Medicines Agency (EMA)
  • Japanese Ministry of Health, Labour and Welfare (MHLW)
  • Japan Patent Office
  • Johns Hopkins University (Baltimore, US)
  • National Institute of Clinical Excellence (NICE)
  • National Institute of Health (NIH)
  • Ophthalmic Drugs Advisory Committee - Division of the FDA
  • Tokyo University of Science
  • UK National Health Service (NHS)
  • United Nations Department of Economic and Social Affairs, Population Division
  • US Food and Drug Agency (FDA)
  • US National Eye Institute (NEI)
  • US Preventive Services Task Force
  • World Health Organization (WHO)
Back to Top